Gastrointestinal safety profile of meloxicam: A meta-analysis and systematic review of randomized controlled trials

American Journal of Medicine

Volumn 107, Issue 6 SUPPL. 1, 1999, Pages 48-54

  Schoenfeld, Philip ^a,b  

^a WALTER REED ARMY MEDICAL CENTER   (United States)

^b Uniformed Services University of the Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM;

CONFERENCE PAPER; DYSPEPSIA; GASTROINTESTINAL DISEASE; HUMAN; LOW BACK PAIN; MEDICAL INFORMATION; META ANALYSIS; OSTEOARTHRITIS; PRIORITY JOURNAL;

EID: 0033428384     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0002-9343(99)00367-8     Document Type: Conference Paper

References (26)

1. Furst DE. Meloxicam: selective COX-2 inhibition in clinical practice. Semin Arthritis Rheum. 1997;26(suppl 1):21-27.
2. Engelhardt G. Pharamacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheum. 1996;35(suppl 1):4-12.
3. Bevis P, Bird H, Lapham G. An open study to assess the safety and tolerability of meloxicam 15 mg in subjects with rheumatic disease and mild renal insufficiency. Br J Rheum. 1996;35(suppl 1):56-60.
4. Huskisson EC, Ghozlan R, Kurthen R, Degner F, Bluhmki E. A long-term study to evaluate the safety and efficacy of meloxicam therapy in patients with rheumatoid arthritis. Br J Rheum. 1996;35(suppl 1):29-34.
5. Reginster J, Distel M, Bluhmki E. A double-blind, three-week study to compare the efficacy and safety of meloxicam 7.5 mg and meloxicam 15 mg in patients with rheumatoid arthritis. Br J Rheum. 1996;35(suppl 1):17-21.
6. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheum. 1996;35(suppl 1):68-77.
7. Oxman A, Cook D, Guyatt G. Users' guides to the medical literature: how to use an overview. JAMA. 1994;272:1367-1371.
8. Dickersin K, Berlin J. Meta-analysis: State-of-the-science. Epidemiol Rev. 1992;14:154-176.
9. Hosie J, Distel M, Blumki E. Efficacy and tolerability of meloxicam versus piroxicam in patients with osteoarthritis of the hip or knee: a six-month double blind study. Clin Drug Invest. 1997;13:175-184.
10. Hawkey C, Kahan A, Steinbruck K, et al. Gastrointestinal tolerability of meloxicam compared to diclofenac in osteoarthritis patients. Br J Rheum. 1998;37:937-945.
11. Dequeker J, Hawkey C, Kahan A, et al. Improvement in gastrointestinal tolerability of the selective COX-2 inhibitor, meloxicam, compared with piroxicam: results of the safety and efficacy large-scale evaluation of COX-inhibiting therapies (SELECT) trial in osteoarthritis. Br J Rheum. 1998;37: 946-951.
12. Linden B, Distel M, Bluhmki E. A double-blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheum. 1996;35(suppl 1):35-38.
13. Bosch H, Sigmund R, Hettich M. Efficacy and tolerability of intramuscular and oral meloxicam in patients with acute lumbago: a comparison with intramuscular and oral piroxicam. Curr Med Res Opin. 1997;14:29-38.
14. Colberg K, Hettich M, Sigmund R, Degner F. The efficacy and tolerability of an 8-day administration of intravenous and oral meloxicam: a comparison with intramuscular and oral diclofenac in patients with acute lumbago. Curr Med Res Opin. 1996;13:363-377.
15. Carraba M, Paresce E, Angelini M, Galanti A, Marini MG, Cigarini P. A comparison of the local tolerability, safety, and efficacy of meloxicam and piroxicam suppositories in patients with osteoarthritis: a single-blind, randomized, multicentre study. Curr Med Res Opin. 1995;13:343-354.
16. Wojtulewski J, Schattenkirchner M, Barcelo P, et al. A six-month, double-blind trial to compare the efficacy and safety of meloxicam 7.5 mg daily and naproxen 750 mg daily in patients with rheumatoid arthritis. Br J Rheum. 1996;35(suppl 1):22-28.
17. Goei H, Lund B, Distel M, Bluhmki E. A double-blind, randomized trial to compare meloxicam 15 mg with diclofenac 100 mg in the treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage. 1997;5:283-288.
18. Lipscomb GR, Wallis N, Armstrong G, Rees WDW. Gastrointestinal tolerability of meloxicam and piroxicam: a double-blind placebo-controlled study. Br J Clin. 1998;46:133-137.
19. Patoia I, Santucci L, Furno P, et al. A 4-week double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheum. 1996;35(suppl 1):61-67.
20. Hosie J, Distel M, Bluhmki E. Meloxicam in osteoarthritis: a 6-month double-blind comparison with diclofenac sodium. Br J Rheum. 1996;35(suppl 1):39-45.
21. Gabriel SE, Jaakkimainen L, Bombardier C. Risk for serious gastrointestinal complications related to the use of nonsteroidal anti-inflammatory drugs: a meta-analysis. Ann Intern Med. 1991;115:787-796.
22. Larkai E, Smith J, Lidsky M, Sessoms S, Graham D. Dyspepsia in NSAID users: the size of the problem. J Clin Gastroenterol. 1989;11:158-162.
23. Moher D, Fortin P, Jadad AR, et al. Assessing the completeness of reporting of trials published in languages other than English: implications for the conduct of systematic reviews. Lancet. 1996;347:363-366.
24. Dickersin K. The existence of publication bias and risk factors for its occurrence. JAMA. 1990;263:1385-1389.
25. Jada AR, McQuay HJ. Meta-analysis to evaluate analgesic interventions: a systematic qualitative review of their methodology. J Clin Epidemiol. 1996;49:235-243.
26. Quang-Hiang J, Hunt R. Gastrointestinal complications associated with nabumetone. Am J Med. 1999;107(suppl): 55S-64S.